Michael Smolinski, Ph.D.
Senior Vice President of Chemical Development & Pharmaceutical Sciences
Michael joins Nirogy after 14 years at Athenex Inc. where he developed a strong proficiency in drug development with a robust track record of subject matter expertise in CMC, nonclinical, medicinal chemistry, and intellectual property.
During Michael’s tenure at Athenex, he progressed from an entry-level Ph.D. chemist at the then private start-up company with a single clinical product, to Chief Scientific Officer of a publicly-traded company with 500+ employees and a robust product portfolio of 10 products primarily in the oral oncology arena, as well as KlisyriⓇ (tirbanibulin), a topical drug recently approved by FDA/EMA. During this time he served as contributor/lead on CMC and nonclinical subject matter for 9 INDs and 2 New Drug Applications (NDAs) in the US and Marketing Authorization Applications (MAAs) in Europe.
Michael has an established track record of success in research and invention of proprietary drug formulation compositions, processes, methods and uses and advancing them into clinical trials with a keen eye toward bridging science, marketing, medical need, and proprietary positions to identify opportunities for product development.
Michael holds a Ph.D. in Chemistry from the State University of New York at Buffalo and completed post-doctoral training at The Scripps Research Institute in Florida.